Country: Malta
Language: English
Source: Medicines Authority
STADA Arzneimittel AG Stadastraße 2-18, 61118 Bad Vilbel, Germany
B01AE07
DABIGATRAN ETEXILATE 75 mg
HARD CAPSULE
DABIGATRAN ETEXILATE 75 mg
POM
ANTITHROMBOTIC AGENTS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2022-02-17
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DABIGATRAN ETEXILATE STADA 75 MG HARD CAPSULES dabigatran etexilate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. ▪ Keep this leaflet. You may need to read it again. ▪ If you have any further questions, ask your doctor or pharmacist. ▪ This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. ▪ If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dabigatran Etexilate Stada is and what it is used for 2. What you need to know before you take Dabigatran Etexilate Stada 3. How to take Dabigatran Etexilate Stada 4. Possible side effects 5. How to store Dabigatran Etexilate Stada 6. Contents of the pack and other information 1. WHAT DABIGATRAN ETEXILATE STADA IS AND WHAT IT IS USED FOR Dabigatran Etexilate Stada contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation. Dabigatran Etexilate Stada is used in adults to: prevent the formation of blood clots in the veins after knee or hip replacement surgery. Dabigatran Etexilate Stada is used in children to: ▪ treat blood clots and to prevent blood clots from reoccurring. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DABIGATRAN ETEXILATE STADA DO NOT TAKE DABIGATRAN ETEXILATE STADA ▪ if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6). ▪ if you have severely reduced kidney function. ▪ if you are currently bleeding. ▪ if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes). ▪ if you have an increased Read the complete document
1 1. NAME OF THE MEDICINAL PRODUCT Dabigatran Etexilate Stada 75 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 75 mg of dabigatran etexilate (as mesilate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Off white to pale yellow coloured pellets filled in white to off white hard capsule size 2. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. For age appropriate dose forms, see section 4.2. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Dabigatran Etexilate Stada capsules can be used in adults and paediatric patients aged 8 years or older who are able to swallow the capsules whole. When changing between the formulations, the prescribed dose may need to be altered. The dose stated in the relevant dosing table of a formulation should be prescribed for the age and weight of the child. _PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY _ _ _ The recommended doses of Dabigatran Etexilate Stada and the duration of therapy for primary prevention of venous thromboembolism in orthopaedic surgery are shown in table 1. 2 TABLE 1: DOSE RECOMMENDATIONS AND DURATION OF THERAPY FOR PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY TREATMENT INITIATION ON THE DAY OF SURGERY 1-4 HOURS AFTER COMPLETED SURGERY MAINTENANCE DOSE STARTING ON THE FIRST DAY AFTER SURGERY DURATION OF MAINTENANCE DOSE Patients following elective knee replacement surgery single capsule of 110 mg Dabigatran Etexilate Stada 220 mg Dabigatran Etexilate Stada once daily taken as 2 capsules of 110 mg 10 days Patients following elective hip replacement surgery 28-35 days _DOSE REDUCTION RECOMMENDED _ Patients with moderate renal impairment (creatinine clearance (Cr Read the complete document